Trial Profile
Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2020
Price :
$35
*
At a glance
- Drugs Antithrombin alfa (Primary)
- Indications Preeclampsia
- Focus Registrational; Therapeutic Use
- Acronyms PRESERVE-1
- Sponsors rEVO Biologics
- 08 Aug 2020 Primary endpoint (The primary outcome measure is the increase in gestational age) has not been met according to the results published in the American Journal of Obstetrics and Gynecology
- 08 Aug 2020 Results published in the American Journal of Obstetrics and Gynecology
- 07 Feb 2017 Status changed from active, no longer recruiting to completed.